Repeat Entrepreneurship And Talent Retention Key To Success Of SV Health Investors
Interview With Houman Ashrafian, Managing Partner At SV Health Investors
In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
You may also be interested in...
In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.
In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.
Sweden-based Elicera Therapeutics is developing next-generation oncolytic viruses and “fourth-generation” CAR-T cells. CEO Jamal El-Mosleh sat down with In Vivo ahead of the company’s IPO.